Literature DB >> 20435861

Variability of lung function predicts loss of asthma control following withdrawal of inhaled corticosteroid treatment.

Cindy Thamrin1, D Robin Taylor, Stuart L Jones, Béla Suki, Urs Frey.   

Abstract

BACKGROUND One aspect of a multidimensional approach to understanding asthma as a complex dynamic disease is to study how lung function varies with time. Variability measures of lung function have been shown to predict response to beta(2)-agonist treatment. An investigation was conducted to determine whether mean, coefficient of variation (CV) or autocorrelation, a measure of short-term memory, of peak expiratory flow (PEF) could predict loss of asthma control following withdrawal of regular inhaled corticosteroid (ICS) treatment, using data from a previous study. METHODS 87 adult patients with mild to moderate asthma who had been taking ICS at a constant dose for at least 6 months were monitored for 2-4 weeks. ICS was then withdrawn and monitoring continued until loss of control occurred as per predefined criteria. Twice-daily PEF was recorded during monitoring. Associations between loss of control and mean, CV and autocorrelation of morning PEF within 2 weeks pre- and post-ICS withdrawal were assessed using Cox regression analysis. Predictive utility was assessed using receiver operator characteristics. RESULTS 53 out of 87 patients had sufficient PEF data over the required analysis period. The mean (389 vs 370 l/min, p<0.0001) and CV (4.5% vs 5.6%, p=0.007) but not autocorrelation of PEF changed significantly from prewithdrawal to postwithdrawal in subjects who subsequently lost control, and were unaltered in those who did not. These changes were related to time to loss of control. CV was the most consistent predictor, with similar sensitivity and sensitivity to exhaled nitric oxide. CONCLUSION A simple, easy to obtain variability measure of daily lung function such as the CV may predict loss of asthma control within the first 2 weeks of ICS withdrawal.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435861     DOI: 10.1136/thx.2009.129668

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  6 in total

1.  Fluticasone/formoterol association favors long-lasting decrease in bronchial reactivity to methacholine and weekly PEF variability.

Authors:  Sara Cortese; Alessia Gatta; Loredana Della Valle; Rocco Mangifesta; Luca Di Giampaolo; Enrico Cavallucci; Claudia Petrarca; Roberto Paganelli; Mario Di Gioacchino
Journal:  Int J Immunopathol Pharmacol       Date:  2016-06-07       Impact factor: 3.219

Review 2.  What long-term changes in lung function can tell us about asthma control.

Authors:  David A Kaminsky; Charles G Irvin
Journal:  Curr Allergy Asthma Rep       Date:  2015-03       Impact factor: 4.806

3.  Fluctuation Analysis of Peak Expiratory Flow and Its Association with Treatment Failure in Asthma.

Authors:  David A Kaminsky; Lucy L Wang; Jason H T Bates; Cindy Thamrin; David M Shade; Anne E Dixon; Robert A Wise; Stephen Peters; Charles G Irvin
Journal:  Am J Respir Crit Care Med       Date:  2017-04-15       Impact factor: 21.405

4.  Systems Biology and Clinical Practice in Respiratory Medicine. The Twain Shall Meet.

Authors:  Cindy Thamrin; Urs Frey; David A Kaminsky; Helen K Reddel; Andrew J E Seely; Béla Suki; Peter J Sterk
Journal:  Am J Respir Crit Care Med       Date:  2016-11-01       Impact factor: 21.405

5.  A stochastic mixed effects model to assess treatment effects and fluctuations in home-measured peak expiratory flow and the association with exacerbation risk in asthma.

Authors:  Jacob Leander; Mats Jirstrand; Ulf G Eriksson; Robert Palmér
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-12-13

Review 6.  Benralizumab: a unique IL-5 inhibitor for severe asthma.

Authors:  Laren D Tan; Jennifer M Bratt; Dorottya Godor; Samuel Louie; Nicholas J Kenyon
Journal:  J Asthma Allergy       Date:  2016-04-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.